MCY-M11 is the first drug from MaxCyte’s CARMA cell therapy platform. It is being used to treat 15 women with ovarian cancer and peritoneal mesothelioma, which forms around the tissue lining of the womb.
The women in this second cohort will receive a higher dose of the drug than those who were part of the first wave of patients.
There were no dose-limiting toxicities or safety concerns observed in the first set of cancer sufferers, MaxCyte confirmed.
“Successfully completing patient dosing in our first cohort and initiating dosing in a second higher-dose cohort are important milestones for MaxCyte, representing tangible progress for our lead CAR therapeutic and our proprietary CARMA autologous cell therapy platform,” said chief medical officer Claudio Dansky Ullmann.
“We are very excited about the potential of MCY-M11 as a new, effective therapeutic in solid tumours where the majority of patients still have very limited treatment options.”